Detection of SARS-CoV-2 Specific Memory B cells to Delineate Long-Term COVID-19 Immunity
| Autor: | Ulrik Stervbo, Magdi Elsallab, Timm H. Westhoff, Mohamed Abou-El-Enein, Guido Heine, Krystallenia Paniskaki, Nina Babel, Sarah Skrzypczyk, Moritz Anft, Toralf Roch, Adrian-Atila-Nicolas Doevelaar, Felix S. Seibert, Enrico Fritsche, Oliver Witzke, Constantin J. Thieme, Nicola Brindle |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.diagnostic_test
business.industry viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) fungi biochemical phenomena metabolism and nutrition medicine.disease_cause Acquired immune system Flow cytometry body regions medicine.anatomical_structure Immune system Immunity Immunology Pandemic medicine skin and connective tissue diseases business B cell Coronavirus |
| Popis: | Background: The ongoing COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, represents a serious worldwide health concern. A deeper understanding of the immune response to SARS-CoV-2 will be required to refine vaccine development and efficacy as well as to evaluate long-term immunity in convalescent patients. With this in mind, we investigated the formation of SARS-CoV-2 specific BMEMORY cells from patient blood samples. Methods: A standard flow cytometry-based protocol for the detection of SARS-CoV-2 specific B cells was applied using fluorochrome-coupled SARS-CoV-2 spike (S) full-length protein. Cohorts of 26 central European convalescent mild/moderate COVID-19 patients and 14 healthy donors were assessed for the levels of SARS-CoV-2 S- specific BMEMORY cells. Results: Overall B cell composition was not affected by SARS-CoV-2 infection in convalescent patients. Our analysis of SARS-CoV-2 specific BMEMORY cells in samples collected at different time points revealed that S-protein specific B cells remain in peripheral blood at least up to 6 months after COVID-19 diagnosis. Conclusions: Detection of SARS-CoV-2 specific BMEMORY cells may improve our understanding of the long-term adaptive immunity in response to SARS-CoV-2, allowing for an improved public health response and vaccine development during the COVID-19 pandemic. Further validation of the study in larger and more diverse populations and a more extended observation period will be required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|